UCLA Health hospitals place No. 1 in Los Angeles, No. 7 nationally in prominent ranking
UCLA Health hospitals in Westwood and Santa Monica placed No. 1 in Los Angeles, No. 2 in California and No. 7 in the nation in the 2017 –18 U.S. News and World Report rankings.“UCLA Health is proud to be recognized for providing world-class treatment to patients from greater Los Angeles, across the state and around the globe,” said Johnese Spisso, president ofUCLA Health, CEO of UCLA Hospital System and associate vice chancellor of UCLA Health Sciences. “Our long-standing commitment to excellence ensures that our patients and their families receive the most compassionate, comprehensive care possible from every memb...
Source: UCLA Newsroom: Health Sciences - August 8, 2017 Category: Universities & Medical Training Source Type: news
New imaging tracer allows early assessment of abdominal aortic aneurysm risk
(Society of Nuclear Medicine) Yale University researchers have developed a way in which medical imaging with SPECT/CT could potentially be used to assess a patient's rupture risk for abdominal aortic aneurysm. Delaying surgical treatment can be life-threatening, and this new type of imaging could allow physicians to diagnose disease and better plan its management. The study is presented in the featured article of the August issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2017 Category: International Medicine & Public Health Source Type: news
Northwestern, University of Calgary win $3m grant for cardiac valve imaging project
Patients who are born with a bicuspid aortic valve have 2 flaps in their cardiac valve instead of 3 – and researchers from Northwestern University and the University of Calgary are planning a 5-year study to evaluate an imaging approach for preventing the complications of this genetic condition.
With a $3.3 million grant from the National Institutes of Health, the team plans to use 4D-Flow MRI to visualize 3D blood flow in real time and analyze tissue to develop a personalized treatment for patients with BAV.
“Not all BAV patients are the same, yet they are currently treated the same when it comes to timing and...
Source: Mass Device - June 30, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Funding Roundup Imaging National Institutes of Health (NIH) Northwestern University universityofcalgary Source Type: news
Aortica raises $1m, looks for $4m more
Aortica has raised $1 million in a new round of mixed financing, according to an SEC filing posted this week.
Money in the round comes from 11 unnamed investors, with the 1st sale recorded on June 13 this year.
The company is looking for an additional $3 million in the round before closing it, according to the SEC filing. Aortica has not yet stated how it plans to spend funds raised in the round.
In February, Aortica said that midterm data from a physician-sponsored investigational device exemption trial was “highly favorable.”
In the trial, researchers are examining physician-modified endovascular grafts for treating ...
Source: Mass Device - June 27, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Vascular Aortica Source Type: news
Skin cell model advances study of genetic mutation linked to heart disease, stroke risk
(UT Southwestern Medical Center) Using a new skin cell model, researchers have overcome a barrier that previously prevented the study of living tissue from people at risk for early heart disease and stroke. This research could lead to a new understanding of disease progression in aortic aneurysm -- ballooning of the large artery in the chest that carries blood from the heart to the body. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 26, 2017 Category: International Medicine & Public Health Source Type: news
Endologix touts low rate of endoleaks, mortality in 2-year Nellix study results
Endologix (NSDQ:ELGX) today announced the presentation of 2-year data from the EVAS Forward IDE trial of its Nellix stent graft for repairing abdominal aortic aneurysms, touting a high rate of freedom from endoleaks, ruptures and mortalities.
Results from the trial were presented by study principal investigator Dr. Jeffrey Carpenter of New Jersey’s Cooper Medical Schoo and Cooper Health System at the Society of Vascular Surgery’s 2017 Vascular annual meeting this week.
“The overall 2-year results for EVAS with Nellix are very encouraging. In particular, the refined IFU appears to offer excellent patient...
Source: Mass Device - June 5, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Stent Grafts Vascular Endologix Source Type: news
Gore wins Japanese regulatory nod for Gore Excluder IBE
W.L. Gore & Associates said today it won Japanese regulatory approval for its Gore Excluder iliac branch endoprosthesis and that the 1st implants of the device had been performed in the region.
The Newark, Del.-based company said that the Excluder IBE was the 1st off-the-shelf iliac branch solution approved in the country, and the only device indicated for the endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms.
“Providing a simple and straightforward procedure, the IBE preserves flow to the internal iliac arteries during EVAR. In many patients, it is imperative that iliac artery bloo...
Source: Mass Device - May 24, 2017 Category: Medical Devices Authors: Fink Densford Tags: Regulatory/Compliance Stent Grafts Vascular W.L. Gore & Associates Source Type: news
7 medtech stories we missed this week: May 19, 2017
[Image from unsplash.com]From FDA clearances to touting study data, here are 7 medtech stories we missed this week but thought were still worth mentioning.
1. XpandOrtho wins FDA 510(k) clearance
XpandOrtho announced in a May 17 press release that it has received FDA 510(k) clearance for its electronic soft tissue balancing instrument for total knee replacement surgery. The sterile-packaged wireless disposable device uses miniature sensors and actuators to balance knee joints during full-range motions. Using constant pressure bellows systems, the device communicates with a display for multiaxial balance and selection of th...
Source: Mass Device - May 19, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Clinical Trials Food & Drug Administration (FDA) Regulatory/Compliance Research & Development Body Vision Medical Exactech Inc. Lombard Medical Technologies MedTech NxThera Inc. Rivanna Medical Visionsense XpandOrtho Source Type: news
MassDevice.com +5 | The top 5 medtech stories for May 18, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Medtronic owes spine doc inventor $24m for patent infringement
Medtronic must fork over nearly $24 million to the physician inventor behind a group of patents covering a technique for treating spine defects.
Dr. Mark Barry sued...
Source: Mass Device - May 18, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Source Type: news
Endologix dives on 2-year setback for Nellix stent graft
Endologix (NSDQ:ELGX) shares were off more than 30% this morning after the company yesterday revealed a 2-year setback for its Nellix stent graft for repairing abdominal aortic aneurysms.
Irvine, Calif.-based Endologix said meetings with the FDA and “further internal analysis” led it to decide to launch a “confirmatory” trial for Nellix, which was initially delayed last November when the federal safety watchdog asked for 2-year follow-up data from the EVAS-Forward investigational device exemption study.
Endologix said yesterday that the confirmatory study will aim to cover the existing instruct...
Source: Mass Device - May 18, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Stent Grafts Wall Street Beat Endologix Source Type: news
FDA: Fluoroquinolones Not Tied to Retinal Detachment, Aortic Aneurysm (FREE)
By the Editors
Fluoroquinolones don ' t appear to cause retinal detachment or aortic aneurysm or dissection, the FDA said on Thursday as part of its ongoing safety review … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 12, 2017 Category: Primary Care Source Type: news
FDA: Fluoroquinolones Not Linked to Retinal Detachment FDA: Fluoroquinolones Not Linked to Retinal Detachment
Available evidence does not support reports that fluoroquinolone antibiotics may result in retinal detachment or aortic aneurysm or dissection, the FDA said.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 11, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
MassDevice.com +5 | The top 5 medtech stories for April 26, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Baxter sees shares lift on Street-beating Q1 earnings release
Baxter shares have risen today after the medical device company topped expectations on Wall Street with its 1st quarter earnings results.
The Deerfield, Ill.-based c...
Source: Mass Device - April 26, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Medtronic touts 5-year Endurant II AAA registry data
Medtronic (NYSE:MDT) today released 5-year data from the Engage global registry study of its Endurant II abdominal aortic aneurysm stent graft, touting long-term durability and consistent outcomes with the device.
Results from the study, which the company claims is the most robust post-market registry of endovascular aortic repairs to date, was presented at the 2017 Charing Cross Symposium in London this week.
“Medtronic aims to increase access to treatment for patients with aortic disease. This goal has been reinforced by our commitment to developing robust clinical programs – such as the Engage registry ̵...
Source: Mass Device - April 26, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Endoscopic / Arthroscopic Stent Grafts Vascular Medtronic Source Type: news
Women Fare Poorly with Aortic Aneurysm
British study says their treatment, compared to men, needs drastic improvementSource: HealthDay Related MedlinePlus Pages: Aortic Aneurysm, Women's Health (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 26, 2017 Category: Consumer Health News Source Type: news
